|
hepatocellular carcinoma |
62 |
|
medical sciences |
25 |
|
transarterial chemoembolization |
23 |
|
survival |
22 |
|
hepatectomy |
19 |
|
liver transplantation |
19 |
|
surgery |
18 |
|
cirrhosis |
17 |
|
gastroenterology medical sciences |
16 |
|
hcc |
16 |
|
liver resection |
16 |
|
recurrence |
16 |
|
sorafenib |
16 |
|
elderly |
15 |
|
liver transplant |
15 |
|
next-generation sequencing |
15 |
|
covid-19 |
14 |
|
gastroenterology |
14 |
|
immune activation |
14 |
|
intestine |
14 |
|
outcomes |
14 |
|
replication |
14 |
|
sars-cov |
14 |
|
survival analysis |
14 |
|
advanced hepatocellular carcinoma |
13 |
|
child-pugh a |
13 |
|
hepatitis b |
13 |
|
laparoscopic liver resection |
13 |
|
blood transfusion |
12 |
|
cytology and histology |
12 |
|
liver cancer |
12 |
|
oncology medical sciences |
12 |
|
radiology and nuclear medicine pharmacy and pharmacology biology |
12 |
|
acute flare |
11 |
|
bridging therapy |
11 |
|
cancer survival |
11 |
|
decompensation |
11 |
|
hepatocellular carcinoma (hcc) |
11 |
|
high-intensity focused ultrasound |
11 |
|
laparoscopy |
11 |
|
liver failure |
11 |
|
long-term outcome |
11 |
|
meld |
11 |
|
resection |
11 |
|
ablation |
10 |
|
advanced hcc |
10 |
|
cancer stem cells |
10 |
|
gene mutation |
10 |
|
hepatitis |
10 |
|
milan criteria |
10 |
|
molecular biology |
10 |
|
molecular pathology |
10 |
|
new technology |
10 |
|
radiofrequency ablation |
10 |
|
signaling |
10 |
|
11c-acetate |
9 |
|
cancer invasion |
9 |
|
cancer stem cell |
9 |
|
colorectal cancer |
9 |
|
contrast ct |
9 |
|
hifu |
9 |
|
liver |
9 |
|
liver metastasis |
9 |
|
living donor liver transplantation |
9 |
|
medicine & public health |
9 |
|
morbidity |
9 |
|
mortality |
9 |
|
nafld |
9 |
|
nash |
9 |
|
non-invasive treatment |
9 |
|
non-viral liver disease |
9 |
|
pet/ct |
9 |
|
prognosis |
9 |
|
tumor heterogeneity |
9 |
|
tumorigenesis |
9 |
|
acetic acid c 11 |
8 |
|
advanced cancer |
8 |
|
adverse events |
8 |
|
antiviral agents - adverse effects - therapeutic use |
8 |
|
bile ducts - surgery |
8 |
|
cadaver donor |
8 |
|
cancer recurrence |
8 |
|
carcinoma, hepatocellular - complications/diagnosis - surgery |
8 |
|
carcinoma, hepatocellular - mortality - therapy |
8 |
|
carcinoma, hepatocellular - surgery |
8 |
|
carcinoma, hepatocellular - surgery - virology |
8 |
|
chemoembolization, therapeutic - adverse effects - mortality |
8 |
|
child-pugh b |
8 |
|
deceased donor liver transplantation |
8 |
|
disease severity |
8 |
|
endocrinology |
8 |
|
fluorodeoxyglucose f 18 |
8 |
|
gist |
8 |
|
guanine - adverse effects - analogs and derivatives - therapeutic use |
8 |
|
hepatectomy - methods |
8 |
|
hepatitis b, chronic - complications - diagnosis - drug therapy - surgery |
8 |
|
infusions, intra-arterial |
8 |
|
laparoscopic resection |
8 |
|
liver cirrhosis |
8 |
|
liver cirrhosis - surgery - virology |
8 |
|
liver disease |
8 |
|
liver neoplasms - complications/diagnosis - surgery |
8 |
|
liver neoplasms - mortality - therapy |
8 |
|
liver neoplasms - surgery |
8 |
|
living donor |
8 |
|
neoplasm recurrence, local - surgery |
8 |
|
outcome |
8 |
|
prevention |
8 |
|
rsk2 |
8 |
|
seroconversion (sc) |
8 |
|
stereotactic body radiation therapy |
8 |
|
targeted therapy |
8 |
|
thrombosis - diagnosis - etiology - surgery |
8 |
|
tki |
8 |
|
tyrosine-kinase inhibitor |
8 |
|
unresectable |
8 |
|
waiting list |
8 |
|
abdominal abscess |
7 |
|
abdominal bleeding |
7 |
|
abdominal surgery |
7 |
|
adjuvant therapy |
7 |
|
adult |
7 |
|
american society of anaesthesiologists (asa) |
7 |
|
anti-angiogenesis |
7 |
|
biliary anastomotic stricture |
7 |
|
cancer staging |
7 |
|
cancer stemness |
7 |
|
carcinoma, hepatocellular - diagnosis - pathology - surgery |
7 |
|
carcinoma, hepatocellular - mortality - pathology - therapy |
7 |
|
cardiac surgery |
7 |
|
catheter ablation |
7 |
|
catheters, indwelling |
7 |
|
cholangiocarcinoma |
7 |
|
cholecystitis, acute - surgery |
7 |
|
cholecystostomy - instrumentation - methods |
7 |
|
cohort studies |
7 |
|
combined modality therapy |
7 |
|
combined resection |
7 |
|
complication |
7 |
|
de novo hbv |
7 |
|
de novo hepatocellular carcinoma |
7 |
|
domino liver transplant |
7 |
|
entecavir |
7 |
|
experience |
7 |
|
extended criteria organ |
7 |
|
general surgery |
7 |
|
glycolysis |
7 |
|
graft-to-recipient weight ratio |
7 |
|
granulin-epithelin precursor |
7 |
|
head of pancreas |
7 |
|
hepatitis b infection |
7 |
|
hepatitis b vaccination |
7 |
|
high-intensity focused ultrasound ablation - methods |
7 |
|
humans |
7 |
|
hypoxia |
7 |
|
icc |
7 |
|
immunotherapy |
7 |
|
indocyanine green clearance |
7 |
|
limon |
7 |
|
liver neoplasms - diagnosis - pathology - surgery |
7 |
|
liver neoplasms - mortality - pathology - therapy |
7 |
|
living donor liver transplant |
7 |
|
long-term survival |
7 |
|
metastases |
7 |
|
model for end-stage liver disease |
7 |
|
mutation screening |
7 |
|
palliative care |
7 |
|
percutaneous transhepatic cholecystostomy (ptc) |
7 |
|
pfkfb |
7 |
|
portal vein resection |
7 |
|
propensity score matching |
7 |
|
ptbd |
7 |
|
pulse spectrophotometry |
7 |
|
recurrent hcc |
7 |
|
retransplantation |
7 |
|
retrospective studies |
7 |
|
right liver graft |
7 |
|
right-lobe |
7 |
|
size |
7 |
|
small-for-size syndrome |
7 |
|
survival outcomes |
7 |
|
thalidomide |
7 |
|
thoracic surgery |
7 |
|
transthyretin |
7 |
|
treatment outcome |
7 |
|
usg-guided |
7 |
|
val30ala |
7 |
|
vascular surgery |
7 |
|
whipple operation |
7 |
|
acute pancreatitis |
6 |
|
adjuvant chemotherapy |
6 |
|
advanced pancreatic cancer |
6 |
|
alpps |
6 |
|
anastomosis, surgical |
6 |
|
asian |
6 |
|
bevacizumab |
6 |
|
bile leak |
6 |
|
biliary complications |
6 |
|
biliary reconstruction |
6 |
|
biliary stricture |
6 |
|
biological therapy |
6 |
|
breast cancer |
6 |
|
carcinoma |
6 |
|
carcinoma, hepatocellular - epidemiology - surgery |
6 |
|
case-matched study |
6 |
|
cdk1 inhibitor |
6 |
|
cholangiograms |
6 |
|
cholestasis - etiology |
6 |
|
close resection margin |
6 |
|
colorectal liver metastasis |
6 |
|
complex liver resection |
6 |
|
deceased-donor liver transplantation |
6 |
|
desmosplastic reaction |
6 |
|
diagnostic imaging |
6 |
|
donor hepatectomy |
6 |
|
duct-to-duct anastomosis |
6 |
|
ductal anomaly |
6 |
|
en-bloc resection |
6 |
|
end-stage liver disease |
6 |
|
endoscopic retrograde cholangiography |
6 |
|
endoscopic treatment |
6 |
|
erc |
6 |
|
erlotinib |
6 |
|
family history |
6 |
|
gemcitabine |
6 |
|
graft |
6 |
|
graft survival |
6 |
|
graft-weight-to-recipient-weight ratio |
6 |
|
hepaticojejunostomy |
6 |
|
hepatocellular |
6 |
|
hepatocellullar carconoma |
6 |
|
hepatocholangiocarcinoma |
6 |
|
hepatology |
6 |
|
hong kong - epidemiology |
6 |
|
hypothyroidism |
6 |
|
inflow |
6 |
|
internal medicine |
6 |
|
intrahepatic cholangiocarcinoma |
6 |
|
invasion |
6 |
|
keywords |
6 |
|
laparoscopic hepatectomy |
6 |
|
ldlt |
6 |
|
liver neoplasms - epidemiology - surgery |
6 |
|
liver resection (lr) |
6 |
|
liver transplantation (lt) |
6 |
|
liver transplantation - adverse effects |
6 |
|
liver transplantation - statistics and numerical data |
6 |
|
living |
6 |
|
living donors |
6 |
|
living-donor liver transplantation |
6 |
|
lung metastasis |
6 |
|
modulation |
6 |
|
neoplasms |
6 |
|
nomogram |
6 |
|
pdx models |
6 |
|
pediatric donor |
6 |
|
portal vein |
6 |
|
post-transplant recurrence |
6 |
|
prediction |
6 |
|
predictive model |
6 |
|
primary transplantation |
6 |
|
proctology |
6 |
|
radiofrequency ablation (rfa) |
6 |
|
recurrent hepatocellular carcinoma |
6 |
|
right liver donation |
6 |
|
right-liver |
6 |
|
risk factor |
6 |
|
ro3306 |
6 |
|
salvage transplantation |
6 |
|
simultaneous resection |
6 |
|
single-cell sequencing |
6 |
|
small-for-size grafts |
6 |
|
sorafenib-refractory |
6 |
|
stage resection |
6 |
|
standard |
6 |
|
synchronous colorectal liver metastasis |
6 |
|
systemic therapy |
6 |
|
thyroid diseases |
6 |
|
transplantation |
6 |
|
tumour thrombus |
6 |
|
alpha-fetoprotein (afp) |
5 |
|
animal experiment |
5 |
|
animal model |
5 |
|
anterior approach |
5 |
|
apoptosis |
5 |
|
augmented reality |
5 |
|
biliary obstruction |
5 |
|
blunt trauma |
5 |
|
catheter ablation - methods |
5 |
|
cell proliferation |
5 |
|
chemosensitization |
5 |
|
complications |
5 |
|
controlled study |
5 |
|
customized therapies |
5 |
|
cyclin d1 |
5 |
|
deceased-donor liver re-transplantation |
5 |
|
deleterious mutations |
5 |
|
double bypass |
5 |
|
gene silencing |
5 |
|
graft failure |
5 |
|
hemostasis |
5 |
|
hepatic artery thrombosis |
5 |
|
hepatic malignancy |
5 |
|
hepatopancreatoduodenectomy |
5 |
|
iatrogenic disease - prevention and control |
5 |
|
laparoscopic surgery |
5 |
|
liver laceration |
5 |
|
liver trauma |
5 |
|
living-donor liver re-transplantation |
5 |
|
lobectomy |
5 |
|
macrophage polarization |
5 |
|
malignancy |
5 |
|
meta-analysis |
5 |
|
metal stent |
5 |
|
molecular mechanisms |
5 |
|
molecular oncology |
5 |
|
multiple injuries |
5 |
|
non-operative management |
5 |
|
oncological outcomes |
5 |
|
oncology |
5 |
|
open conversion |
5 |
|
pancreatic cancer |
5 |
|
pancreaticojejunostomy |
5 |
|
pancreatoduodenectomy |
5 |
|
penetrative trauma |
5 |
|
post-hepatectomy |
5 |
|
post-operative complication |
5 |
|
predicting scoring system |
5 |
|
radiography, abdominal |
5 |
|
remnant |
5 |
|
residual |
5 |
|
risk factors |
5 |
|
segmentectomy |
5 |
|
single-cell rna sequencing |
5 |
|
smad inhibitor |
5 |
|
smad2/3/smad4 |
5 |
|
spleen - injuries - pathology - radiography - surgery |
5 |
|
targeted sequencing |
5 |
|
wedge resection |
5 |
|
78-kda glucose-regulated protein |
4 |
|
afp |
4 |
|
alpha-fetoprotein |
4 |
|
associating liver partition and portal vein ligation for staged hepatectomy |
4 |
|
bilirubin level |
4 |
|
biomarker |
4 |
|
cabozantinib |
4 |
|
cell line establishment |
4 |
|
checkpoint inhibitors |
4 |
|
chemotherapy |
4 |
|
chromosome gain |
4 |
|
combination therapy |
4 |
|
complex liver surgery |
4 |
|
consensus |
4 |
|
cytotoxicity |
4 |
|
emergency laparoscopic cholecystectomy |
4 |
|
ercp |
4 |
|
hepatectom |
4 |
|
hepatopancreaticobiliary surgery |
4 |
|
high intensity focused ultrasound |
4 |
|
hilar cholangiocarcinoma |
4 |
|
hong kong |
4 |
|
icg fluorescence |
4 |
|
imaging |
4 |
|
indocyanine green |
4 |
|
inflammatory responses |
4 |
|
interferon-gamma |
4 |
|
interventional radiology |
4 |
|
intolerance |
4 |
|
liver tumor |
4 |
|
mass spectrometry |
4 |
|
member d |
4 |
|
mhc class i chain-related molecule a |
4 |
|
minimally invasive liver surgery |
4 |
|
natural-killer group 2 |
4 |
|
open liver resection |
4 |
|
perforin |
4 |
|
postoperative cytokines |
4 |
|
preoperative biliary drainage |
4 |
|
protein interaction |
4 |
|
radiosurgery |
4 |
|
ruptured hepatocellular carcinoma |
4 |
|
survivor |
4 |
|
technique |
4 |
|
thermal ablation |
4 |
|
tolerance |
4 |
|
tyrosine kinase inhibitors |
4 |
|
urology and nephrology |
4 |
|
vascular reconstruction |
4 |
|
vascular resection |
4 |
|
anatomy |
3 |
|
central bisectionectomy |
3 |
|
color doppler ultrasonography |
3 |
|
difficulty score |
3 |
|
doxorubicin-eluting beads |
3 |
|
flexible endoscopy |
3 |
|
hepatobiliary |
3 |
|
icg |
3 |
|
immune checkpoint inhibitors |
3 |
|
inflow control |
3 |
|
intensity |
3 |
|
interventional endoscopy |
3 |
|
ipilimumab |
3 |
|
laparoscopic |
3 |
|
neoadjuvant chemotherapy |
3 |
|
nivolumab |
3 |
|
non-colorectal liver metastasis |
3 |
|
resection margin |
3 |
|
surgical instruments |
3 |
|
surgical procedure |
3 |
|
testis - blood supply |
3 |
|
therapeutics |
3 |
|
time factors |
3 |
|
unresectable hcc |
3 |
|
varicocele |
3 |
|
varicocele - surgery - ultrasonography |
3 |
|
β-catenin |
3 |
|
anatomic landmark |
2 |
|
anatomic liver resection |
2 |
|
angiogram |
2 |
|
carcinoid tumor |
2 |
|
carcinoma, hepatocellular - therapy |
2 |
|
case report |
2 |
|
choledochal cyst |
2 |
|
choledocholithiasis |
2 |
|
choristoma - complications - pathology |
2 |
|
cystic artery |
2 |
|
difficulty |
2 |
|
down-staging therapy |
2 |
|
drug transporter |
2 |
|
embolization |
2 |
|
embolization, therapeutic - methods |
2 |
|
endoscopic ultrasound |
2 |
|
evidence |
2 |
|
extended criteria |
2 |
|
fatal outcome |
2 |
|
future liver remnant |
2 |
|
gastrointestinal bleeding |
2 |
|
gene signature |
2 |
|
high-intensity focused ultrasound (hifu) |
2 |
|
hklc |
2 |
|
imaging and advanced technology/applied therapeutics |
2 |
|
immunosuppressant |
2 |
|
incomplete excision |
2 |
|
intensive care units |
2 |
|
intrahepatic cholangiocarcinoma (icc) |
2 |
|
laparoscopic exploration of common bile duct |
2 |
|
laparoscopic liver |
2 |
|
liver - cancer - treatment |
2 |
|
liver - cirrhosis - treatment |
2 |
|
liver anatomy |
2 |
|
liver cancer staging |
2 |
|
liver neoplasm |
2 |
|
liver neoplasms - therapy |
2 |
|
liver surgery |
2 |
|
microwave ablation (mwa) |
2 |
|
minimally-invasive hepatectomy |
2 |
|
minimally-invasive liver |
2 |
|
multidrug resistance |
2 |
|
obscured origin |
2 |
|
optimization |
2 |
|
pancreas - pathology |
2 |
|
pancreatitis |
2 |
|
patient selection |
2 |
|
peritonitis - etiology - pathology |
2 |
|
plasticity |
2 |
|
posterosuperior segments |
2 |
|
precision oncology |
2 |
|
pregnancy |
2 |
|
primary hepatic neuroendocrine tumor |
2 |
|
pseudoaneurysm |
2 |
|
re-excision |
2 |
|
review |
2 |
|
robotic |
2 |
|
robotic liver resection |
2 |
|
sbrt |
2 |
|
simultaneous |
2 |
|
synchronous |
2 |
|
systemic review |
2 |
|
tace |
2 |
|
transarterial chemoembolization (tace) |
2 |
|
transarterial radioembolization (tare) |
2 |
|
treatment response |
2 |
|
yttrium |
2 |
|
yttrium radioisotopes - therapeutic use |
2 |
|
3d laparoscopy |
1 |
|
a propensity score matching analysis |
1 |
|
acute abdomen |
1 |
|
adenocarcinoma |
1 |
|
adjuvant transcatheter arterial chemoembolization |
1 |
|
advanced liver cirrhosis |
1 |
|
algorithm decision |
1 |
|
anatomical hepatectomy |
1 |
|
anterolateral segment |
1 |
|
benchmark |
1 |
|
bile ducts, intrahepatic |
1 |
|
biliary fibrosis |
1 |
|
body mass index |
1 |
|
cancer control |
1 |
|
cancer surgery |
1 |
|
carcinoma, hepatocellular - pathology - radionuclide imaging |
1 |
|
cholangiopathy |
1 |
|
circulating tumor cells |
1 |
|
coarsened exact-matched |
1 |
|
colon cancer |
1 |
|
colorectal liver metastases |
1 |
|
combined treatments |
1 |
|
composite measure |
1 |
|
conventional tace |
1 |
|
conversion therapy |
1 |
|
deb-tace |
1 |
|
delphi technique |
1 |
|
difficulty scoring system |
1 |
|
downstaging |
1 |
|
editorial |
1 |
|
etiology |
1 |
|
extended right hepatectomy |
1 |
|
fluorine radioisotopes - diagnostic use - pharmacokinetics |
1 |
|
free gas |
1 |
|
gallstones |
1 |
|
gas forming |
1 |
|
global |
1 |
|
global survey |
1 |
|
hand-assisted |
1 |
|
hepatic resection |
1 |
|
hepatolithiasis |
1 |
|
high intensity focuses ultrasound (hifu) |
1 |
|
human |
1 |
|
hybrid |
1 |
|
icd-11 |
1 |
|
international consensus conference |
1 |
|
international consensus guidelines |
1 |
|
inverse probability treatment weighting |
1 |
|
iwate |
1 |
|
laparoscopic approach |
1 |
|
laparoscopic liver resections |
1 |
|
laparoscopic liver surgery |
1 |
|
laparoscopic-assisted |
1 |
|
learning curve |
1 |
|
left hepatectomy |
1 |
|
left lateral sectionectomy |
1 |
|
liver abscess |
1 |
|
liver metastases |
1 |
|
liver neoplasms - pathology - radionuclide imaging |
1 |
|
liver transplant (lt) |
1 |
|
location |
1 |
|
mafld |
1 |
|
major hepatectomy |
1 |
|
major resections |
1 |
|
management |
1 |
|
mechanism |
1 |
|
middle hepatic vein |
1 |
|
minimal-invasive |
1 |
|
minimally invasive |
1 |
|
minimally invasive hepatectomy |
1 |
|
minimally invasive liver |
1 |
|
minimally invasive surgery |
1 |
|
minor hepatectomy |
1 |
|
neoplasm metastasis - radionuclide imaging |
1 |
|
net |
1 |
|
neuroendocrine tumors |
1 |
|
non-colorectal |
1 |
|
non-neuroendocrine |
1 |
|
pancreaticoduodenectomy |
1 |
|
patient outcome |
1 |
|
patient-derived xenograft |
1 |
|
positron-emission tomography and computed tomography - methods |
1 |
|
propensity-score matched |
1 |
|
quality assessment |
1 |
|
quality of care |
1 |
|
re-resection |
1 |
|
rectal cancer |
1 |
|
recurrent pyogenic cholangitis |
1 |
|
recurrent salvage liver transplantation |
1 |
|
right hepatectomy |
1 |
|
right posterior sectionectomy |
1 |
|
risk score |
1 |
|
robotic liver resections |
1 |
|
robotic liver surgery |
1 |
|
salmonella enteritidis |
1 |
|
second hepatectomy |
1 |
|
textbook outcome |
1 |
|
therapeutic strategy |
1 |
|
treatment |
1 |
|
tumor size |
1 |
|
unresectable hepatocellular carcinoma |
1 |
|
update |
1 |
